脂肪酸延伸酶ELOVL6调控多发性骨髓瘤硼替佐米耐药
本研究探讨脂代谢在多发性骨髓瘤(MM)硼替佐米(BTZ)耐药中的作用。发现BTZ无应答患者MM细胞及BTZ耐药细胞系中ELOVL6水平降低;恢复ELOVL6可通过上调神经酰胺使耐药细胞重新对BTZ敏感,并增强内质网应激与细胞死亡。
要点
- BTZ耐药MM细胞中ELOVL6表达下调,与临床无应答相关。
- 恢复ELOVL6水平可重新敏化BTZ耐药MM细胞。
- ELOVL6依赖的神经酰胺变化是BTZ诱导内质网应激和死亡的前提。
核心结论
- ELOVL6是MM细胞BTZ耐药的主要临床相关调控因子,耐药可能源于细胞改变神经酰胺组成的能力受损。
研究设计与样本
- 比较BTZ无应答与应答患者MM细胞及BTZ耐药与亲本培养MM细胞系的ELOVL6水平。
- 在亲本MM细胞中敲低ELOVL6,在BTZ耐药MM细胞中恢复ELOVL6,并在组织培养和浆细胞瘤小鼠模型异种移植中评估。
- 首次比较亲本与BTZ耐药MM细胞系在BTZ诱导下的脂质组变化。
主要发现
- BTZ无应答患者MM细胞中ELOVL6水平低于应答患者,BTZ耐药细胞系低于亲本细胞。
- 亲本MM细胞敲低ELOVL6可抑制BTZ诱导的内质网应激和细胞毒性。
- BTZ耐药MM细胞恢复ELOVL6后在培养和浆细胞瘤小鼠模型中均对BTZ敏感化。
- 恢复ELOVL6主要通过上调ELOVL6依赖的神经酰胺种类重新敏化耐药细胞,这是BTZ诱导内质网应激和细胞死亡的前提。
临床怎么用
- ELOVL6水平可能作为MM患者BTZ耐药的临床相关标志物。
- 恢复ELOVL6或调节神经酰胺组成可能是克服BTZ耐药的策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Resistance to the proteasome inhibitor bortezomib (BTZ) represents a major obstacle in the treatment of multiple myeloma (MM). The contribution of lipid metabolism in the resistance of MM cells to BTZ is mostly unknown. Here we report that levels of fatty acid elongase 6 (ELOVL6) were lower in MM cells from BTZ-nonresponsive vs BTZ-responsive patients and in cultured MM cells selected for BTZ resistance compared with parental counterparts. Accordingly, depletion of ELOVL6 in parental MM cells suppressed BTZ-induced endoplasmic reticulum (ER) stress and cytotoxicity, whereas restoration of ELOVL6 levels in BTZ-resistant MM cells sensitized them to BTZ in tissue culture settings and, as xenografts, in a plasmacytoma mouse model. Furthermore, for the first time, we identified changes in the BTZ-induced lipidome between parental and BTZ-resistant MM cell lines underlying a functional difference in their response to BTZ. We demonstrated that restoration of ELOVL6 levels in BTZ-resistant MM cells resensitized them to BTZ largely via upregulation of ELOVL6-dependent ceramide species, which was a prerequisite for BTZ-induced ER stress and cell death in these cells. Our data characterize ELOVL6 as a major clinically relevant regulator of MM cell resistance to BTZ, which can emerge from the impaired ability of these cells to alter ceramide composition in response to BTZ.
引用
- Lipchick BC, Utley A, Han Z, et al. The fatty acid elongase ELOVL6 regulates bortezomib resistance in multiple myeloma. Blood Adv. 2021. PMID: 33821992. doi:10.1182/bloodadvances.2020002578
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。